JATT Acquisition (JATT) Competitors $2.28 -0.06 (-2.56%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends JATT vs. PHAT, HUMA, ATXS, ANNX, DNA, PROK, MREO, PRTC, ANAB, and CRMDShould you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Phathom Pharmaceuticals (PHAT), Humacyte (HUMA), Astria Therapeutics (ATXS), Annexon (ANNX), Ginkgo Bioworks (DNA), ProKidney (PROK), Mereo BioPharma Group (MREO), PureTech Health (PRTC), AnaptysBio (ANAB), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. JATT Acquisition vs. Phathom Pharmaceuticals Humacyte Astria Therapeutics Annexon Ginkgo Bioworks ProKidney Mereo BioPharma Group PureTech Health AnaptysBio CorMedix Phathom Pharmaceuticals (NASDAQ:PHAT) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Do analysts rate PHAT or JATT? Phathom Pharmaceuticals currently has a consensus target price of $23.00, indicating a potential upside of 208.72%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer PHAT or JATT? Phathom Pharmaceuticals received 88 more outperform votes than JATT Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformPhathom PharmaceuticalsOutperform Votes8872.13% Underperform Votes3427.87% JATT AcquisitionN/AN/A Which has stronger earnings & valuation, PHAT or JATT? JATT Acquisition has lower revenue, but higher earnings than Phathom Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$26.27M19.39-$201.59M-$5.69-1.31JATT AcquisitionN/AN/A$6.85MN/AN/A Do insiders & institutionals believe in PHAT or JATT? 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to PHAT or JATT? In the previous week, Phathom Pharmaceuticals had 9 more articles in the media than JATT Acquisition. MarketBeat recorded 9 mentions for Phathom Pharmaceuticals and 0 mentions for JATT Acquisition. Phathom Pharmaceuticals' average media sentiment score of 0.90 beat JATT Acquisition's score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Phathom Pharmaceuticals Positive JATT Acquisition Neutral Is PHAT or JATT more profitable? JATT Acquisition has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-1,292.14% N/A -79.57% JATT Acquisition N/A -49.58%2.84% SummaryPhathom Pharmaceuticals beats JATT Acquisition on 10 of the 13 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get JATT Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JATT vs. The Competition Export to ExcelMetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$39.33M$2.94B$5.13B$19.18BDividend YieldN/A1.90%4.93%3.60%P/E RatioN/A46.7389.5841.24Price / SalesN/A412.591,115.0117.60Price / Cash27.08182.1042.8221.28Price / Book-4.303.894.805.32Net Income$6.85M-$42.21M$120.04M$989.88M7 Day PerformanceN/A-2.15%-1.91%-3.54%1 Month Performance-21.38%4.20%11.48%-3.68%1 Year Performance-52.80%18.39%30.59%12.14% JATT Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JATTJATT AcquisitionN/A$2.28-2.6%N/A-51.6%$39.33MN/A0.003High Trading VolumePHATPhathom Pharmaceuticals2.9962 of 5 stars$8.14+3.2%$23.00+182.6%-9.3%$556.61M$680,000.00-1.43110Gap UpHUMAHumacyte3.3459 of 5 stars$4.34+5.9%$13.00+199.5%+69.3%$546.23M$1.57M-3.06150Analyst ForecastGap UpATXSAstria Therapeutics2.0771 of 5 stars$9.67+1.6%$25.60+164.7%+58.0%$545.68MN/A-4.6330News CoverageANNXAnnexon2.1121 of 5 stars$5.06+14.0%$15.80+212.3%+81.6%$539.37MN/A-4.8260Analyst ForecastNews CoverageGap DownHigh Trading VolumeDNAGinkgo Bioworks0.5512 of 5 stars$9.37-0.7%$4.58-51.2%N/A$538.59M$251.46M-0.721,218Gap DownPROKProKidney2.0368 of 5 stars$1.84+2.8%$4.50+144.6%-15.6%$536.66MN/A-3.353Gap DownMREOMereo BioPharma Group2.0992 of 5 stars$3.45-7.8%$7.40+114.5%+68.3%$535.25M$1M0.0040High Trading VolumePRTCPureTech Health1.9898 of 5 stars$22.00+8.1%$45.00+104.5%+3.8%$526.72M$3.33M0.00100Gap DownHigh Trading VolumeANABAnaptysBio2.3125 of 5 stars$16.65+6.8%$45.09+170.8%-25.4%$506.64M$57.17M-2.76100Analyst ForecastCRMDCorMedix1.8468 of 5 stars$8.31-0.8%$15.20+82.9%+147.0%$504.23M$12.26M-10.3130Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies PHAT Alternatives HUMA Alternatives ATXS Alternatives ANNX Alternatives DNA Alternatives PROK Alternatives MREO Alternatives PRTC Alternatives ANAB Alternatives CRMD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:JATT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JATT Acquisition Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share JATT Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
